Stock News & Analysis

Piper Sandler to investors: Maybe you should have bought Intel stock last year?

Both companies are winning in AI chips, but one of them is winning by a margin that is getting harder to close.

Both funds track investment-grade corporate debt maturing within five years, with VCSH charging 0.03% and IGSB at 0.04%.

Jensen Huang saw opportunities in June's tech sector sell-off, but the next few months told a more complicated story for Nvidia.

SPGM delivered 24.4% over one year versus SCHE's 20.3%, though SCHE offers a lower expense ratio and higher dividend yield for income seekers.

Innodata is delivering record growth and improving profitability while BigBear.ai works through a reset, but both companies lean heavily on a small number of large customers.

Enbridge's scale, diversification, and durable dividend make it a solid investment.

Cooper won't sell its Surgical arm, and it was forced to cut forward guidance. Wall Street didn't like that.

Rate-hike odds for next week's Fed meeting jumped to 70%.

Memory maker Micron reports fiscal 2026 fourth-quarter earnings on Sept. 30.

AppLovin is one of the most profitable advertising platforms in the market, while Reddit just turned profitable and is building new revenue streams that could broaden its business significantly.

Broadcom's latest quarter revenue hit $29.6 billion — nearly 11 times Marvell's $2.7 billion — with both companies posting steady gains over the past two years.

This under-the-radar consumer staples stock boasts a Superscore of 78 from our Hidden Gems Primary database, part of The Motley Fool's Moneyball Database system. Here's why.

Cameco generates $779M in annual free cash flow with a fortress balance sheet, while TMC burns cash in pursuit of unproven deep-sea technology.

C3.ai burns cash and carries a $1.8 billion accumulated deficit, while Atlassian generates $1.3 billion in free cash flow despite higher valuation multiples.

Can an extra $100 on the starting price outrun memory costs management itself expects to keep climbing?

Boeing's debt burden and negative cash flow contrast sharply with GE's fortress balance sheet and $7.3 billion in free cash flow.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

The executive's disposition follows a 16% decline in the stock price over the trailing 12 months.

The tech-heavy index's performance is likely to remain strong. It's also likely to remain volatile.